Alejandro Amador
Vice President of R&D & Operations Navega Therapeutics
Seminars
Thursday 24th September 2026
Targeting Ion Channel Expression Through Epigenetic Gene Editing to Improve Specificity & Durability
11:30 am
- Comparing DNA, RNA, and protein level strategies to clarify where epigenetic gene editing offers distinct advantages for ion channel modulation
- Addressing specificity, delivery, and durability challenges when regulating ion channel expression rather than channel activity
- Evaluating translational potential of DNA targeting approaches to reduce off target effects in pain related ion channel programs
Thursday 24th September 2026
Panel: Comparing Modality Selection Decisions to Match Biology & Indication Requirements
12:00 pm
- Examining how biology, delivery constraints & safety risk shaped final modality choices
- Weighing durability, tissue access, reversibility & tolerability across competing strategies
- Identifying modality decision principles that remain consistent across CNS & peripheral programs
Thursday 24th September 2026
Fireside Chat: Reflecting on Clinical Experience to Shape Next‑Generation Ion Channel Programs
4:00 pm
- Discussing how programs evolved in response to clinical data and operational realities
- Sharing insights gained through adaptation, iteration, and risk management during development
- Informing future discovery and development choices with experience-based perspective
Thursday 24th September 2026
Chair’s Closing Remarks
4:30 pm
